

GIMV NV  
Form SC 13G  
February 14, 2007

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13G**  
(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)**

**Under the Securities Exchange Act of 1934  
(Amendment No. )\***

**TorreyPines Therapeutics, Inc.**

(Name of Issuer)

**Common Shares, par value \$0.001**

(Title of Class of Securities)

**89235K105**

(CUSIP Number)

**December 31, 2006**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

## Edgar Filing: GIMV NV - Form SC 13G

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP No. 89235K105

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)  
GIMV, NV
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    - (a)
    - (b)
  3. SEC Use Only
  4. Citizenship or Place of Organization  
Belgium
- |   |    |  |                                       |
|---|----|--|---------------------------------------|
|   | 5. |  | Sole Voting Power<br>0                |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | 6. |  | Shared Voting Power<br>2,628,603      |
|   | 7. |  | Sole Dispositive Power<br>0           |
|   | 8. |  | Shared Dispositive Power<br>2,628,603 |
9. Aggregate Amount Beneficially Owned by Each Reporting Person  
2,628,603
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
  11. Percent of Class Represented by Amount in Row (9)  
16.34%
  12. Type of Reporting Person (See Instructions)  
CO

CUSIP No. 89235K105

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)  
Adviesbeheer GIMV Life Sciences, NV
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    - (a)
    - (b)
  3. SEC Use Only
  4. Citizenship or Place of Organization  
Belgium
- |   |    |                                       |
|---|----|---------------------------------------|
|   | 5. | Sole Voting Power<br>0                |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | 6. | Shared Voting Power<br>2,628,603      |
|   | 7. | Sole Dispositive Power<br>0           |
|   | 8. | Shared Dispositive Power<br>2,628,603 |
9. Aggregate Amount Beneficially Owned by Each Reporting Person  
2,628,603
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
  11. Percent of Class Represented by Amount in Row (9)  
16.34%
  12. Type of Reporting Person (See Instructions)  
CO

CUSIP No. 89235K105

- |   |   |    |                        |    |                                  |    |                             |    |                                       |
|---|---|----|------------------------|----|----------------------------------|----|-----------------------------|----|---------------------------------------|
| 1.  | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)<br>Biotech Fonds Vlaanderen, NV   |    |                        |    |                                  |    |                             |    |                                       |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) <input type="radio"/><br>(b) <input checked="" type="radio"/>  |    |                        |    |                                  |    |                             |    |                                       |
| 3.  | SEC Use Only  |    |                        |    |                                  |    |                             |    |                                       |
| 4.  | Citizenship or Place of Organization<br>Belgium   |    |                        |    |                                  |    |                             |    |                                       |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | <table border="0"> <tr> <td style="vertical-align: top;">5.</td> <td>Sole Voting Power<br/>0</td> </tr> <tr> <td style="vertical-align: top;">6.</td> <td>Shared Voting Power<br/>2,628,603</td> </tr> <tr> <td style="vertical-align: top;">7.</td> <td>Sole Dispositive Power<br/>0</td> </tr> <tr> <td style="vertical-align: top;">8.</td> <td>Shared Dispositive Power<br/>2,628,603</td> </tr> </table> | 5. | Sole Voting Power<br>0 | 6. | Shared Voting Power<br>2,628,603 | 7. | Sole Dispositive Power<br>0 | 8. | Shared Dispositive Power<br>2,628,603 |
| 5.  | Sole Voting Power<br>0  |    |                        |    |                                  |    |                             |    |                                       |
| 6.  | Shared Voting Power<br>2,628,603  |    |                        |    |                                  |    |                             |    |                                       |
| 7.  | Sole Dispositive Power<br>0   |    |                        |    |                                  |    |                             |    |                                       |
| 8.  | Shared Dispositive Power<br>2,628,603   |    |                        |    |                                  |    |                             |    |                                       |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2,628,603   |    |                        |    |                                  |    |                             |    |                                       |
| 10.   | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/>   |    |                        |    |                                  |    |                             |    |                                       |
| 11.   | Percent of Class Represented by Amount in Row (9)<br>16.34%   |    |                        |    |                                  |    |                             |    |                                       |
| 12.   | Type of Reporting Person (See Instructions)<br>CO   |    |                        |    |                                  |    |                             |    |                                       |

CUSIP No. 89235K105

- |   |   |                                       |
|---|---|---------------------------------------|
| 1.  | Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)<br>Patrick Van Beneden, Executive Vice President, Life Sciences |                                       |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) <input type="radio"/><br>(b) <input checked="" type="radio"/>                |                                       |
| 3.  | SEC Use Only  |                                       |
| 4.  | Citizenship or Place of Organization<br>Belgium   |                                       |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With | 5.  | Sole Voting Power<br>0                |
|   | 6.  | Shared Voting Power<br>2,628,603      |
|   | 7.  | Sole Dispositive Power<br>0           |
|   | 8.  | Shared Dispositive Power<br>2,628,603 |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2,628,603   |                                       |
| 10.   | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/>   |                                       |
| 11.   | Percent of Class Represented by Amount in Row (9)<br>16.34%   |                                       |
| 12.   | Type of Reporting Person (See Instructions)<br>CO   |                                       |

Edgar Filing: GIMV NV - Form SC 13G

Item 1.

- (a) Name of Issuer  
TorreyPines Therapeutics, Inc.
- (b) Address of Issuer's Principal Executive Offices  
11085 North Torrey Pines Road, Suite 300  
  
La Jolla, CA 92037

Item 2.

- (a) Name of Person Filing  
GIMV, NV
- (b) Address of Principal Business Office or, if none, Residence  
Karel Oomsstraat 37  
  
B-2018 Antwerpen, Belgium
- (c) Citizenship
- (d) Title of Class of Securities
- (e) CUSIP Number

Item 3.

- If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
  - (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
  - (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
  - (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
  - (e)  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  - (f)  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  - (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
  - (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  - (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  - (j)  Group, in accordance with §240.13d-1(b)(1)(ii)(J).  
Not applicable, this statement is filed pursuant to 13d-1(c).

## Edgar Filing: GIMV NV - Form SC 13G

### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned:
- 2,628,603 (see schedule below by fund)
- (b) Percent of class:
- 16.34%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote
  - 0
  - (ii) Shared power to vote or to direct the vote
  - 2,628,603
  - (iii) Sole power to dispose or to direct the disposition of
  - 0
  - (iv) Shared power to dispose or to direct the disposition of
  - 2,628,603

Entity Name	Common Stock	Warrants for Common Stock	Total Shares Beneficially Owned	Beneficial Ownership %
GIMV NV	1,544,403	286,897	1,831,300	
Adviesbeheer GIMV Life Sciences, NV	193,776	35,782	229,558	
Biotech Fonds Vlaanderen, NV	477,704	90,041	567,745	
<b>Total GIMV NV combined holdings:</b>	<b>2,215,883</b>	<b>412,720</b>	<b>2,628,603</b>	<b>16.34 %</b>

### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following .

N/A

### Item 6. Ownership of More than Five Percent on Behalf of Another Person

N/A

### Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

N/A

### Item 8. Identification and Classification of Members of the Group

N/A

### Item 9. Notice of Dissolution of Group

N/A

### Item 10. Certification



## Edgar Filing: GIMV NV - Form SC 13G

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

7

---

**Signature**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2007  
(Date)

GIMV

By: /s/ Dirk Boogmans  
Name: Dirk Boogmans  
Title: President & Chief Executive Officer

By: /s/ Dirk Beeusaert  
Name: Dirk Beeusaert  
Title: Chief Legal Officer